Nitto-denko Corporation

Teijin Limited

Chugai Seiyaku Kabushiki Kaisha

Daiichi Pure Chemicals Co., Ltd.

Yoshiro Niitsu

Hiroyuki Tanaka

Yasunobu Tanaka

Joseph E Payne

Mohammad Ahmadian

Victor Knopov

Richard P Witte

Violetta Akopian

Loren A Perelman

John Gaudette

Zheng Hou

Elena Feinstein

Igor Mett

Hagar Kalinski

Wenbin Ying

Kenjiro Minomi

Priya Prakash Karmali

Sridhar C Nagarajan

Junji Kato

Sharon Avkin-Nahum

Yun Liu

Lei Yu

Hirokazu Takahashi

Sharon Avkin-Nachum

Shai Erlich

Elizabeth C Squiers

Ning Chen

Yasushi Sato

Rishu Takimoto

Xiaomei Jin

Kenjirou Minomi

Roger C Adami

Bharat Majeti

Jihua Liu

Li Wang

Akihiro Yoneda

Hirotoshi Ishiwatari

Hiroki Nishita

Hideaki Suzuki

Yasuhiko Masuho

Sang Van

Gang Zhao

Koji Ushizawa

Kenji Hosoda

Hirokazu Yago

Jian Liu

Hitomi Honda

Erika Terada

Masato Higuchi

Roger Adami

Fu Chen

Miyono Miyazaki

Keiko Kajiwara

Nianchun Ma

Hiroshi Maruyama

Ichiro Urushizaki

Hisashi Hanada

Yutaka Kohgo

Priya Karmali

Takuya Matsunaga

C Nagarajan Sridhar

Yun Lui

Sharon Avkin-nachum

John A Gaudette

This invention provides compositions for use in distributing active agents for treating a malignant tumor in a subject. The compositions contain RNAi molecules targeted to a human GST-&#x3c0;, along with RNAi molecules targeted to a human p21, and a pharmaceutically acceptable carrier. The carrier can include nanoparticles composed of an ionizable lipid, a structural lipid, one or more stabilizer lipids, and a lipid for reducing immunogenicity of the nanoparticles. This invention further provides methods for preventing or treating a malignant tumor by administering a therapeutically effective amount of an RNAi composition.

RNA interference compositions and methods for malignant tumors

Here described is a composition comprising a compound of formula I: wherein Rand Ris independently selected from a group consisting of Cto Calkyl, Cto Calkenyl, and oleoyl group; Rand Rare independently selected from a group consisting of Cto Calkyl, and Cto Calkanol; X is selected from a group consisting of &#x2014;CH&#x2014;, &#x2014;S&#x2014;, and &#x2014;O&#x2014; or absent; Y is selected from &#x2014;(CH), &#x2014;S(CH), &#x2014;O(CH)&#x2014;, thiophene, &#x2014;SO(CH)&#x2014;, and ester; n=1-4; a=1-4; b=1-4; c=1-4; and Zis a counterion.

Cationic lipids for therapeutic agent delivery formulations

Here described are compounds consisting of the structure(targeting molecule)-linker-(targeting molecule),wherein the targeting molecule is a retinoid or a fat soluble vitamin having a specific receptor on the target cell; wherein m and n are independently 0, 1, 2 or 3; and wherein the linker comprises a polyethylene glycol (PEG) or PEG-like molecule, as well as compositions and pharmaceutical formulations including these compounds which are useful for the targeting and delivery of therapeutic agents; and methods of using these compositions and pharmaceutical formulations.

Compounds for targeting drug delivery and enhancing siRNA activity

Cell death is induced and/or cell growth is suppressed for a cell having a mutation in the BRAF gene. A drug suppressing GST-&#x3c0; is comprised as an active ingredient.

Cell death inducing agent for cells having BRAF gene mutation, growth suppressing agent for same cells and pharmaceutical composition for therapy of diseases caused by growth defect of same cells

Here described is a method of delivery of a drug to a stellate cell using a composition comprising a compound of formula I: wherein Rand Rare independently selected from Cto Calkyl, Cto Calkenyl, and oleoyl; Rand Rare independently selected from Cto Calkyl and Cto Calkanol; X is selected from &#x2014;CH&#x2014;, &#x2014;S&#x2014;, and &#x2014;O&#x2014;, or X is absent; Y is selected from &#x2014;(CH), &#x2014;S(CH)&#x2014;, &#x2014;O(CH)&#x2014;, -thiophene-, &#x2014;SO(CH)&#x2014;, and ester; n&#x2550;1-4; a&#x2550;1-4; b&#x2550;1-4; c&#x2550;1-4; and Zis a counterion.

What is described is a method for treating a fibrotic disease by administering a pharmaceutical composition comprising a drug carrier, which comprises a lipid and a retinoid, and a double-stranded nucleic acid molecule, which comprises an antisense sequence to mRNA encoding human hsp47.

Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier

What is described is a pharmaceutical composition for treating a fibrotic disease comprising a drug carrier, which comprises a lipid and a retinoid, and a double-stranded nucleic acid molecule, which comprises an antisense sequence to mRNA encoding human hsp47.

Retinoid-lipid drug carrier

Here described are compounds consisting of the structure

Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for fibroid lung, which utilized the carrier; and a preparation kit of the therapeutic agent.

Therapeutic agent for fibroid lung

The purpose of the present invention is to provide: a composition for effectively inducing apoptosis and/or proliferation inhibition in cells; and a method in which the composition is used. The present invention relates to: an agent for inducing apoptosis, which contains a GST-&#x3c0;-inhibiting drug and a RB1CC1-inhibiting drug as active ingredients; a pharmaceutical composition which contains the agent; a method for treating a disease associated with an abnormality in apoptosis, in which the agent is used; and others.

Apoptosis inducer

Provided herein are compositions, methods and kits for modulating expression of target genes, particularly heat shock protein 47 (hsp47). The compositions, methods and kits may include nucleic acid molecules (for example, short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA) or short hairpin RNA (shRNA)) that modulate a gene encoding hsp47, for example, the gene encoding human hsp47. The composition and methods disclosed herein may also be used in treating conditions and disorders associated with hsp47 such as liver fibrosis, pulmonary fibrosis, peritoneal fibrosis and kidney fibrosis.

Modulation of HSP47 expression

Provided are: a targeting molecule targeting a target cell which is selected from the group consisting of a stellate cell, a myofibroblast, a cancer-associated fibroblast, a tumor cell and a cell expressing STRA6, said targeting molecule being selected from the group consisting of (1) a peptide containing an amino acid sequence in the cell-binding region of RBP, (2) a variant peptide of the aforesaid peptide (1), said variant peptide having a comparable targetability to peptide (1), and (3) a peptide mimetic having a comparable targetability to peptide (1) or peptide (2); a targeting agent, a carrier, a complex and a medicinal composition each comprising the targeting molecule; a method for treating, examining, diagnosing or monitoring a disease related to the aforesaid target cell; a method for labeling, detecting or imaging the target cell, etc.

Targeting molecule and a use thereof

Here described are compounds of formula I: wherein Rand Rare independently selected from Cto Calkyl, Cto Calkenyl, and oleoyl; Rand Rare independently selected from Cto Calkyl and Cto Calkanol; X is selected from &#x2014;CH&#x2014;, &#x2014;S&#x2014;, and &#x2014;O&#x2014;, or X is absent; Y is selected from &#x2014;(CH), &#x2014;S(CH)&#x2014;, &#x2014;O(CH)&#x2014;, -thiophene-, &#x2014;SO(CH)&#x2014;, and ester; n=1-4; a=1-4; b=1-4; c=1-4; and Zis a counterion. Also described herein are compositions and pharmaceutical formulations including compounds of formula I which are useful for the delivery of therapeutic agents, and methods of using these compositions and formulations.

The present invention relates to a pharmaceutical composition and a method for regenerating normal tissue from fibrotic tissue, the pharmaceutical composition and the method employing a collagen-reducing substance. In accordance with the present invention, normal tissue can be therapeutically regenerated from fibrotic tissue.

Composition for regenerating normal tissue from fibrotic tissue

Growing community of inventors

Hokkaido, Japan

Yoshiro Niitsu